Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GN Tobacco Use Survey

This study has been completed.
Sponsor:
Collaborators:
Global Network for Women's and Children's Health Research
Bill and Melinda Gates Foundation
RTI International
Information provided by (Responsible Party):
NICHD Global Network for Women's and Children's Health
ClinicalTrials.gov Identifier:
NCT00121368
First received: July 15, 2005
Last updated: November 22, 2013
Last verified: November 2013

July 15, 2005
November 22, 2013
February 2004
May 2005   (final data collection date for primary outcome measure)
Tobacco use [ Time Frame: Cross sectional ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00121368 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GN Tobacco Use Survey
Survey on Tobacco Use in the GN Sites

Smoking can contribute to many health problems for mothers and their babies. In developing countries, there is little information about the number of pregnant women that smoke and the reasons why some pregnant women choose to smoke. The purpose of this multi-site tobacco use survey is to obtain information on knowledge, attitudes and behaviors among pregnant women in diverse populations regarding tobacco products.

Smoking is regarded as one of the few potentially preventable factors associated with low birth weight, very preterm birth and perinatal death. In an effort to determine the prevalence of tobacco use (smoking and smokeless tobacco) and to collect relevant data in support of a potential smoking prevention or cessation intervention, a multi-site tobacco use survey is being conducted in several countries. The survey will be used to obtain information on knowledge, attitudes and behaviors among pregnant women in diverse populations regarding tobacco products.

The primary outcome is tobacco use status during pregnancy. Secondary outcomes include: knowledge and attitudes regarding tobacco products, health hazards of tobacco use and environmental tobacco smoke (ETS) exposure.

Sample size of 750 per country was calculated under the assumptions that the prevalence of tobacco use could be as low as 0.05 with a coefficient of variation of approximately 15% and a prevalence of 0.10 with a CV of approximately 11%.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Pregnant women 18-45

Smoking
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6000
May 2005
May 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pregnant women of legal consent and child-bearing age (18-45)
  • Attendance at a participating clinic

Exclusion Criteria:

  • Pregnant women with disabilities such as deafness, serious mental illness, or mental retardation
Female
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Argentina,   Brazil,   Congo,   Ecuador,   Guatemala,   India,   Pakistan,   Zambia
 
NCT00121368
CP01 Tobacco Use
Yes
NICHD Global Network for Women's and Children's Health
NICHD Global Network for Women's and Children's Health
  • National Cancer Institute (NCI)
  • Global Network for Women's and Children's Health Research
  • Bill and Melinda Gates Foundation
  • John E. Fogarty International Center (FIC)
  • National Center for Complementary and Alternative Medicine (NCCAM)
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • RTI International
Principal Investigator: Michele Bloch, MD, PhD National Cancer Institute (NCI)
NICHD Global Network for Women's and Children's Health
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP